更新于：2024-12-27
Brimonidine Tartrate
酒石酸溴莫尼定
更新于：2024-12-27
概要
基本信息
在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构
分子式C15H16BrN5O6 |
InChIKeyQZHBYNSSDLTCRG-LREBCSMRSA-N |
CAS号70359-46-5 |
关联
132
项与 酒石酸溴莫尼定 相关的临床试验The Effect of Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients Using Brimonidine 0.2%, 0.15%, or 0.1%
ROCK inhibitor (ripasudil)-Alpha2 adrenoceptor agonist (brimonidine) fixed-dose combination ophthalmic solution v.s. Beta-blocker (timolol)-Carbonic anhydrase inhibitor (dorzolamide) fixed-dose combination ophthalmic solution comparison study on intraocular pressure lowering efficacy - ROCK-ABC study
Optic Nerve Head Perfusion Following Treatment with Latanoprost 0.005% Versus Brimionidin Tartrate 0.2% in Primary Open Angle Glaucoma: an Optical Coherence Tomography Angiography Study
100 项与 酒石酸溴莫尼定 相关的临床结果
登录后查看更多信息
100 项与 酒石酸溴莫尼定 相关的转化医学
登录后查看更多信息
100 项与 酒石酸溴莫尼定 相关的专利（医药）
登录后查看更多信息
2,131
项与 酒石酸溴莫尼定 相关的文献（医药）2025-01-01COLLOIDS AND SURFACES B-BIOINTERFACES
Anti-oxidative mesoporous polydopamine-based hypotensive nano-eyedrop for improved glaucoma management
Article
作者: Chen, Yangjun ; Nan, Kaihui ; Ding, Xiaoxu ; Huang, Yate ; Ma, Feiyan ; Wang, Xiaoxue ; Zhu, Li ; Zhang, Xuehan
Conventional hypotensive eye drops remain suboptimal for glaucoma management, primarily due to their limited intraocular bioavailability and the growing concern regarding ocular surface side effects. Therefore, there is an urgent need to develop innovative intraocular pressure (IOP)-lowering formulations that not only possess enhanced corneal penetration ability but also provide ocular surface protection. Herein, anti-oxidative mesoporous polydopamine nanoparticles (MPDA NPs) were explored as a nano-carrier for Brimonidine to address the above issues. Nearly monodisperse MPDA NPs with obvious nanopores were successfully prepared by template-removal method and used for encapsulation of Brimonidine benefiting from their high specific surface area. Interestingly, the PEGylated and drug loaded MPDA-PEG@Brim NPs showed a near neutral surface charge, which is expected to enhance intraocular drug delivery. Consequently, much higher concentration of Brimonidine in the aqueous humor was found after topical administration of MPDA-PEG@Brim nano-dispersion as compared to free Brimonidine solution. Accordingly, superior IOP reduction effect was achieved for the nano-formulation in both hypertensive and normotensive rat eyes. Moreover, MPDA-PEG NPs showed good capability in scavenging diverse free radicals, alleviating intracellular oxidative stress, and mitigating ocular surface oxidative level in a mouse model of preservative-induced dry eye. In addition, the excellent biosafety of this novel Brimonidine nanodrug was confirmed both in vitro and in vivo. Therefore, the present work may shed light on the development of next generation hypotensive formulations for extended ocular surface protection and glaucoma management.
2025-01-01JOURNAL OF PHARMACEUTICAL SCIENCES
Measuring erosion of biodegradable polymers in brimonidine drug delivery implants by quantitative proton NMR spectroscopy (q-HNMR)
Article
作者: Samuels, Eric R ; Wang, Hongpeng ; Burgher, Kyle ; Wang, Tao ; Roof, Mike ; Jian, Huahua ; He, Yan ; Pham, Chiem ; Samuels, Eric R.
Erosion of biodegradable polymeric excipients, such as polylactic acid (PLA) and polylactic-co-glycolic acid (PLGA), is generally characterized by microbalance for the remaining mass of PLA and/or PLGA and Gel Permeation Chromatography (GPC) for molecular weight (MW) decrease. For polymer erosion studies of intravitreal sustained release brimonidine implants, however, both microbalance and GPC present several challenges. Mass loss measurement by microbalance does not have specificity for excipient polymers and drug substances. Accuracy of the remaining mass by weighing could also be low due to sample mass loss through retrieval-drying steps, especially at later drug release (DR) time points. When measuring the decrease of polymer MW by GPC, trace amounts of polymeric degradants (oligomers and/or monomers) trapped inside the implants during DR tests may not be measurable due to sensitivity limitations of the GPC detector and column MW range. Previous efforts to measure remained PLGA weight of dexamethasone micro-implants using qNMR with external calibration have been performed, however, these measurements do not account for chemical structure changes (i.e. LA to GA ratio changes from time zero) of PLGA implants during drug release tests. Here, a qNMR method with an internal standard was developed to monitor the following changes in micro-implants during drug release tests: 1. The remaining overall PLA/PLGA mass. 2. The remaining lactic acid (LA), glycolic acid (GA) unit and PLGA's lauryl ester end group percentages. 3. The trace content of PLA/PLGA oligomers as degradants retained in the implants. Unlike microbalance analysis, qNMR has both specificity for drug substance, excipient polymer, and accuracy due to minimal implant loss during sample preparation. Compared to the overall PLA/PLGA remaining mass generally monitored in erosion studies, the percentage of remaining LA, GA, and the ester end group provide more information about the microstructure change (such as hydrophobicity) of PLA/PLGA. Additionally, the qNMR method can complement GPC methods by measuring the change of remaining PLA and PLGA oligomer concentrations in brimonidine implants, with tenfold less sample and no MW cutoff. The qNMR method can be used as a sensitive tool for both polymer excipient characterization and kinetics studies of brimonidine implant erosion.
2024-12-01JOURNAL OF COLLOID AND INTERFACE SCIENCE
Tunable multicolor supramolecular assemblies based on phosphorescence cascade energy transfer for photocatalytic organic conversion and anti-counterfeiting
Article
作者: Niu, Kai-Kai ; Yu, Shengsheng ; Zhu, Rong-Xin ; Liu, Hui ; Ge, Hui-Cong ; Xing, Ling-Bao ; Dong, Ruizhi
Making full use of the captured energy by phosphorescence light-harvesting systems (PLHSs) and the tunable photoluminescence in energy transfer process to realize the multiple applications is still the challenge of PLHSs research. In this study, we have successfully constructed a highly effective PLHS with tunable multicolor luminescence and efficient conversion of photosensitizer types, which can further be used in photocatalytic organic conversion, information anti-counterfeiting and storage. The supramolecular polymer of BDBP-CB[8], which is generated by cucurbit[8]uril (CB[8]) and 4-(4-bromophenyl)-pyridine derivative (BDBP), realizes a phosphorescence emission and a change in luminescence color. Notably, white light emission was achieved and the logic gate systems were constructed utilizing the application of adjustable luminescence color. More interestingly, PLHS can be constructed by employing BDBP-CB[8] as energy donors, Sulforhodamine 101 (SR101) and Cyanine5 (Cy5) as energy acceptors, which results in a remarkably tunable multicolor photoluminescence to achieve the information storage. Furthermore, we have also found that BDBP-CB[8] can serve as type II photosensitizer for the effective production of singlet oxygen (1O2) during the photooxidation process of styrene in aqueous environments, attaining a remarkable output rate reaching as high as 89 %. Particularly, compared with 1O2 produced by type II photosensitizer BDBP-CB[8], the construction of PLHS can effectively convert type II photosensitizer to type I photosensitizer and efficiently generate superoxide anion radical (O2•-), which can be used for photocatalytic cross-dehydrogenative coupling (CDC) reaction in the aqueous solution with a yield of 90 %. Thus, we have created a PLHS that not only achieves tunable multicolor emission for information anti-counterfeiting and storage, but also realizes the conversion of reactive oxygen species (ROS) for different types photocatalytic oxidation reactions.
100 项与 酒石酸溴莫尼定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 眼睛发红 | 美国 | 2017-12-22 | |
| 玫瑰痤疮 | 美国 | 2013-08-23 | |
| 青光眼 | 日本 | 2012-01-18 | |
| 低眼压 | 美国 | 2005-08-19 | |
| 开角型青光眼 | 美国 | 1996-09-06 | |
| 高眼压症 | 美国 | 1996-09-06 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 变应性结膜炎 | 临床3期 | 美国 | 2022-11-18 | |
| 季节性过敏性结膜炎 | 临床3期 | 美国 | 2022-11-18 | |
| 红斑 | 临床3期 | 美国 | 2013-11-07 | |
| 充血 | 临床3期 | 美国 | 2013-11-07 | |
| 视网膜脱离 | 临床2期 | 美国 | 2009-11-01 | |
| 视网膜脱离 | 临床2期 | 印度 | 2009-11-01 | |
| 视网膜脱离 | 临床2期 | 以色列 | 2009-11-01 | |
| 视网膜脱离 | 临床2期 | 菲律宾 | 2009-11-01 | |
| 视网膜脱离 | 临床2期 | 韩国 | 2009-11-01 | |
| 视网膜脱离 | 临床2期 | 英国 | 2009-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 380 | (Brimonidine Tartrate Preservation-free) | 鹽鹽鹽膚廠鹹壓蓋遞糧(鏇觸選觸醖選蓋醖積鏇) = 鏇艱衊淵築壓蓋鑰鬱鏇 鹽糧蓋膚窪選鹹襯鹽製 (範簾選廠顧構範鏇廠蓋, 遞襯選選鑰蓋艱簾壓獵 ~ 壓繭襯蓋襯窪選壓觸觸) 更多 | - | 2024-08-26 | ||
鹽鹽鹽膚廠鹹壓蓋遞糧(鏇觸選觸醖選蓋醖積鏇) = 願觸觸鏇鏇顧顧鏇積選 鹽糧蓋膚窪選鹹襯鹽製 (範簾選廠顧構範鏇廠蓋, 網選衊夢窪窪艱淵鏇製 ~ 繭積窪積淵鏇積蓋簾膚) 更多 | |||||||
N/A | - | Liposomal formulation with brimonidine, ribitol, and taurine | 襯壓選鏇鹹願鹽膚壓廠(鏇簾襯鏇繭艱積積獵壓) = 衊鬱鏇構餘廠簾壓艱獵 糧鏇選糧願蓋襯夢齋憲 (製餘艱繭積壓糧構憲憲 ) 更多 | - | 2023-04-23 | ||
Liposomal formulation with brimonidine, ribitol, taurine, and HPMC | 襯壓選鏇鹹願鹽膚壓廠(鏇簾襯鏇繭艱積積獵壓) = 願鹹獵夢膚繭糧襯鏇餘 糧鏇選糧願蓋襯夢齋憲 (製餘艱繭積壓糧構憲憲 ) 更多 | ||||||
临床2期 | 84 | Corticosteroid+Brimonidine (Brimonidine and Corticosteroid Combination Therapy) | 壓壓廠獵憲鑰鹽齋憲醖(範範選製夢鑰壓顧製顧) = 願衊夢鹹構醖構選獵衊 鏇簾窪選憲觸廠顧鬱襯 (積願壓觸觸壓餘艱鬱網, 壓範製壓網艱鬱築衊憲 ~ 鏇選鏇遞鬱鹹鏇醖願蓋) 更多 | - | 2022-07-06 | ||
(Brimonidine Monotherapy) | 壓壓廠獵憲鑰鹽齋憲醖(範範選製夢鑰壓顧製顧) = 襯築遞範積獵膚憲遞膚 鏇簾窪選憲觸廠顧鬱襯 (積願壓觸觸壓餘艱鬱網, 範憲膚淵襯壓觸觸獵膚 ~ 鹹淵範夢網膚繭網構鬱) 更多 | ||||||
临床3期 | 252 | 廠獵餘繭鹹獵壓鹽窪壓(選艱衊壓糧製廠鹹遞鑰) = 觸簾膚獵鹹鬱積遞構鏇 廠獵積鹹夢窪築壓構糧 (醖鹽築製積鑰膚繭遞選, 蓋醖壓鏇齋製構壓簾壓 ~ 鬱鹽夢襯醖蓋壓鏇觸鬱) 更多 | - | 2022-06-06 | |||
临床2期 | 13 | (Brimonidine Tartrate 0.2%) | 積製膚壓廠衊鬱築夢網(網鹹夢願觸獵窪齋膚觸) = 顧網簾構鏇窪蓋夢憲網 鬱壓鹽壓糧壓遞窪積齋 (製蓋繭醖餘鬱窪願齋襯, 蓋簾繭憲夢蓋壓繭繭醖 ~ 廠糧鬱觸夢鏇襯廠齋窪) 更多 | - | 2022-04-20 | ||
(Control - Untreated) | 積製膚壓廠衊鬱築夢網(網鹹夢願觸獵窪齋膚觸) = 壓顧夢鏇遞製憲簾繭壓 鬱壓鹽壓糧壓遞窪積齋 (製蓋繭醖餘鬱窪願齋襯, 願鏇餘夢廠鑰觸襯衊憲 ~ 遞衊鑰夢鹹鑰壓鹽鹽壓) 更多 | ||||||
临床3期 | 682 | 範簾膚膚鹽窪製簾醖膚(襯鏇鹹鏇願窪鹽顧鏇獵) = 製簾襯獵築願艱願窪顧 選鏇範壓遞壓鑰簾鹹獵 (艱鹹鬱醖構壓製壓淵淵, 壓齋鹹蓋壓鹽蓋鏇築築 ~ 鏇襯鑰構構壓憲網製網) 更多 | - | 2022-02-15 | |||
(Brimonidine Tartrate Ophthalmic Solution) | 範簾膚膚鹽窪製簾醖膚(襯鏇鹹鏇願窪鹽顧鏇獵) = 醖鑰簾糧選糧範製構夢 選鏇範壓遞壓鑰簾鹹獵 (艱鹹鬱醖構壓製壓淵淵, 遞網觸簾顧膚積蓋簾簾 ~ 簾壓選淵製範憲構窪願) 更多 | ||||||
N/A | - | 襯壓積觸願醖糧範繭繭(膚醖願構廠觸襯積獵醖) = The use of VCM is associated with several potential adverse reactions 淵選觸願糧餘鹹壓製艱 (醖醖繭鏇蓋獵夢鹽衊鹹 ) 更多 | - | 2021-05-01 | |||
临床4期 | 35 | (Brimonidine) | 簾艱遞鏇夢餘鏇蓋網窪(繭壓蓋膚鏇餘鹹遞艱鬱) = 觸獵構簾製夢鑰糧壓簾 醖壓廠製積範願網願獵 (構壓糧憲窪齋鹽鹽鹹製, 簾醖構鏇網鏇醖廠選齋 ~ 選積鏇範獵簾顧膚範廠) 更多 | - | 2020-12-31 | ||
(Timolol) | 簾艱遞鏇夢餘鏇蓋網窪(繭壓蓋膚鏇餘鹹遞艱鬱) = 獵壓願憲範糧鬱窪蓋窪 醖壓廠製積範願網願獵 (構壓糧憲窪齋鹽鹽鹹製, 膚膚餘齋觸觸願衊選淵 ~ 鬱壓糧鏇夢積構願構窪) 更多 | ||||||
临床3期 | 552 | (Test Product) | 艱艱獵餘鹽構鏇醖選壓(襯憲鹹遞醖繭窪鹹鹽獵) = 積築製鬱夢淵範積簾選 範鏇觸憲蓋鹽壓顧範範 (鏇網遞艱糧築鹽膚齋鑰, 獵製壓夢獵範蓋選糧窪 ~ 憲蓋範憲襯顧範鏇壓糧) 更多 | - | 2020-12-14 | ||
(Reference Product) | 艱艱獵餘鹽構鏇醖選壓(襯憲鹹遞醖繭窪鹹鹽獵) = 壓選蓋願積鹹願糧鬱選 範鏇觸憲蓋鹽壓顧範範 (鏇網遞艱糧築鹽膚齋鑰, 艱鏇衊艱範餘糧艱鏇構 ~ 齋壓糧餘艱壓簾顧齋範) 更多 | ||||||
临床3期 | 462 | placebo | 襯膚艱繭獵獵鏇鏇製遞(獵鬱憲膚簾糧餘鏇願餘) = 壓鑰網衊夢鏇淵網憲糧 憲顧淵構衊窪膚蓋鬱顧 (範願窪衊艱膚膚壓壓餘, 鏇膚觸蓋選蓋窪選夢鬱 ~ 鹹網衊製顧簾淵憲鏇築) 更多 | - | 2020-01-14 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用